Patent · US Active

Anti-human CD45RC antibodies and uses thereof

US12168694B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
NANTES UNIVERSITE · FR
CENTRE HOSPITALIER ET UNIVERSITAIRE DE BREST · FR

Inventors

Carole GUILLONNEAU · Le Chene, FR
Ignacio ANEGON · Nantes, FR

Key dates

Filing date	Sep 20, 2019
Grant date	Dec 17, 2024
Priority date	—
Expiry date	Apr 22, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Isolated anti-human CD45RC antibodies or binding fragments thereof, nucleic acids and expression vector encoding the same, compositions including the same, and uses thereof as medicaments, including for the prevention and/or treatment of CD45RChigh-related diseases (including autoimmune diseases, undesired immune responses, monogenic diseases, and lymphoma or cancer), in particular for use in preventing and/or treating graft-versus-host disease (GVHD).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.